Comment on: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

By Errante Domenico   Bernardi Daniele   Bianco Antonio   Salvagno Luigi  

Acta Oncologica, Vol. 46, Iss. 4, 2007-01 ,pp. : 565-566

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji   Narabayashi Masaru   Ito Yoshinori   Saji Shigehira   Fujiwara Yasuhiro   Usami Shigeyuki   Katsura Koichi   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

HER2-positive Breast Cancer Brain Metastases: Multiple Responses to Systemic Chemotherapy and Trastuzumab—a Case Report

By Church D.   Bahl A.   Jones A.   Price C.  

Journal of Neuro-Oncology, Vol. 79, Iss. 3, 2006-09 ,pp. : 289-292

Springer Publishing Company

Access to resources Recommend Favorite

Risk factors and survival outcomes in patients with brain metastases from breast cancer

By Minisini A.   Moroso S.   Gerratana L.   Giangreco M.   Iacono D.   Poletto E.   Guardascione M.   Fontanella C.   Fasola G.   Puglisi F.  

Clinical and Experimental Metastasis, Vol. 30, Iss. 8, 2013-12 ,pp. : 951-956

Springer Publishing Company

Access to resources Recommend Favorite

Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A metaanalysis

By          

Oncology Letters, Vol. 5, Iss. 6, 2013-01 ,pp. : 1915-1920

Spandidos Publications

Access to resources Recommend Favorite